Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Keratosis, Actinic 7Neoplasms 5Melanoma 3Warts 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hyperthermia 2Hematologic Neoplasms 2Hemangioma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tuberous Sclerosis 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Seizures 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pelvic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Nonmelanoma Skin Cancers 1Mucositis 1

Interventions

fluorodopa F 18 4Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × Solutions × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡